217 related articles for article (PubMed ID: 21518222)
1. Concordance between HIV-1 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.
Verhofstede C; Brudney D; Reynaerts J; Vaira D; Fransen K; De Bel A; Seguin-Devaux C; De Wit S; Vandekerckhove L; Geretti AM
HIV Med; 2011 Oct; 12(9):544-52. PubMed ID: 21518222
[TBL] [Abstract][Full Text] [Related]
2. High concordance of genotypic coreceptor prediction in plasma-viral RNA and proviral DNA of HIV-1 subtype C: implications for use of whole blood DNA in resource-limited settings.
Gupta S; Neogi U; Srinivasa H; Shet A
J Antimicrob Chemother; 2013 Sep; 68(9):2003-6. PubMed ID: 23633683
[TBL] [Abstract][Full Text] [Related]
3. Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA.
Visseaux B; Charpentier C; Taieb A; Damond F; Bénard A; Larrouy L; Chêne G; Brun-Vézinet F; Matheron S; Descamps D;
AIDS; 2013 Jan; 27(2):292-5. PubMed ID: 23095312
[TBL] [Abstract][Full Text] [Related]
4. Dynamics of HIV tropism under suppressive antiretroviral therapy: implications for tropism testing in subjects with undetectable viraemia.
Seclén E; Del Mar González M; De Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Jul; 65(7):1493-6. PubMed ID: 20488982
[TBL] [Abstract][Full Text] [Related]
5. Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group.
Svicher V; Alteri C; Montano M; D'Arrigo R; Andreoni M; Angarano G; Antinori A; Antonelli G; Allice T; Bagnarelli P; Baldanti F; Bertoli A; Borderi M; Boeri E; Bon I; Bruzzone B; Callegaro AP; Capobianchi MR; Carosi G; Cauda R; Ceccherini-Silberstein F; Clementi M; Chirianni A; Colafigli M; D'Arminio Monforte A; De Luca A; Di Biagio A; Di Nicuolo G; Di Perri G; Di Pietro M; Di Santo F; Fabeni L; Fadda G; Galli M; Gennari W; Ghisetti V; Giacometti A; Gori C; Gori A; Gulminetti R; Leoncini F; Maffongelli G; Maggiolo F; Manca G; Gargiulo F; Martinelli C; Maserati R; Mazzotta F; Meini G; Micheli V; Monno L; Mussini C; Narciso P; Nozza S; Paolucci S; Pal G; Parisi S; Parruti G; Pignataro AR; Pollicita M; Quirino T; Re MC; Rizzardini G; Santangelo R; Scaggiante R; Sterrantino G; Turriziani O; Vatteroni ML; Vecchi L; Viscoli C; Vullo V; Zazzi M; Lazzarini A; Perno CF;
New Microbiol; 2012 Jan; 35(1):17-25. PubMed ID: 22378549
[TBL] [Abstract][Full Text] [Related]
6. High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists.
Seclén E; Garrido C; González Mdel M; González-Lahoz J; de Mendoza C; Soriano V; Poveda E
J Antimicrob Chemother; 2010 Jul; 65(7):1486-92. PubMed ID: 20427374
[TBL] [Abstract][Full Text] [Related]
7. Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice.
Symons J; Vandekerckhove L; Paredes R; Verhofstede C; Bellido R; Demecheleer E; van Ham PM; van Lelyveld SF; Stam AJ; van Versendaal D; Nijhuis M; Wensing AM
Clin Microbiol Infect; 2012 Jun; 18(6):606-12. PubMed ID: 21906210
[TBL] [Abstract][Full Text] [Related]
8. HIV-1 tropism: a comparison between RNA and proviral DNA in routine clinical samples from Chilean patients.
Ferrer P; Montecinos L; Tello M; Tordecilla R; Rodríguez C; Ferrés M; Pérez CM; Beltrán C; Guzmán MA; Afani A
Virol J; 2013 Oct; 10():318. PubMed ID: 24165156
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
[TBL] [Abstract][Full Text] [Related]
10. Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure.
Rozera G; Abbate I; Giombini E; Castagna A; De Luca A; Ceccherini-Silberstein F; Cozzi Lepri A; Cassola G; Torti C; d'Arminio Monforte A; Ippolito G; Capobianchi MR;
J Antimicrob Chemother; 2014 Nov; 69(11):3085-94. PubMed ID: 25015667
[TBL] [Abstract][Full Text] [Related]
11. Evolution of proviral DNA HIV-1 tropism under selective pressure of maraviroc-based therapy.
Baroncelli S; Galluzzo CM; Weimer LE; Pirillo MF; Volpe A; Mercuri A; Cavalli A; Fragola V; Monno L; Degli Antoni A; Ladisa N; Francisci D; Bucciardini R; Floridia M
J Antimicrob Chemother; 2012 Jun; 67(6):1479-85. PubMed ID: 22361986
[TBL] [Abstract][Full Text] [Related]
12. Genotypic Tropism Testing in HIV-1 Proviral DNA Can Provide Useful Information at Low-Level Viremia.
Fabeni L; Berno G; Svicher V; Ceccherini-Silberstein F; Gori C; Bertoli A; Mussini C; Lichtner M; Zaccarelli M; Ammassari A; Pinnetti C; Cicalini S; Mastroianni CM; Andreoni M; Antinori A; Perno CF; Santoro MM
J Clin Microbiol; 2015 Sep; 53(9):2935-41. PubMed ID: 26135872
[TBL] [Abstract][Full Text] [Related]
13. The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients.
Santoro MM; Armenia D; Fabeni L; Santoro M; Gori C; Forbici F; Svicher V; Bertoli A; Dori L; Surdo M; Balestra E; Palamara G; Girardi E; Angarano G; Andreoni M; Narciso P; Antinori A; Ceccherini-Silberstein F; Perno CF
Clin Microbiol Infect; 2012 Aug; 18(8):E289-98. PubMed ID: 22681969
[TBL] [Abstract][Full Text] [Related]
14. Co-receptor switch during HAART is independent of virological success.
Saracino A; Monno L; Cibelli DC; Punzi G; Brindicci G; Ladisa N; Tartaglia A; Lagioia A; Angarano G
J Med Virol; 2009 Dec; 81(12):2036-44. PubMed ID: 19856465
[TBL] [Abstract][Full Text] [Related]
15. Deep Sequencing of the HIV-1 env Gene Reveals Discrete X4 Lineages and Linkage Disequilibrium between X4 and R5 Viruses in the V1/V2 and V3 Variable Regions.
Zhou S; Bednar MM; Sturdevant CB; Hauser BM; Swanstrom R
J Virol; 2016 Aug; 90(16):7142-58. PubMed ID: 27226378
[TBL] [Abstract][Full Text] [Related]
16. Deep-Sequencing Analysis of the Dynamics of HIV-1 Quasiespecies in Naive Patients during a Short Exposure to Maraviroc.
Cascajero A; Rastrojo A; Díez-Fuertes F; Hernández-Novoa B; Aguado B; Moreno S; Alcami J; Pérez-Olmeda M
J Virol; 2018 Jun; 92(11):. PubMed ID: 29563289
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of genotypic prediction of HIV-1 tropism using population sequencing of replicates.
Ferreira JL; Coelho LP; Rodrigues R; Cabral GB; Cavalcanti Jde S; Guimaraes PM; Brigido LF
J Virol Methods; 2012 Feb; 179(2):325-9. PubMed ID: 22138669
[TBL] [Abstract][Full Text] [Related]
18. Comparison of two genotypic algorithms to determine HIV-1 tropism.
Soulié C; Derache A; Aimé C; Marcelin AG; Carcelain G; Simon A; Katlama C; Calvez V
HIV Med; 2008 Jan; 9(1):1-5. PubMed ID: 18199166
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia.
Spudich SS; Huang W; Nilsson AC; Petropoulos CJ; Liegler TJ; Whitcomb JM; Price RW
J Infect Dis; 2005 Mar; 191(6):890-8. PubMed ID: 15717264
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of R5 and X4 HIV variants in antiretroviral treatment experienced patients with virologic failure.
Ferrer P; Tello M; Montecinos L; Tordecilla R; Rodríguez C; Beltrán C; Guzmán MA; Ferrés M; Pérez CM; Afani A
J Clin Virol; 2014 Jul; 60(3):290-4. PubMed ID: 24793966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
